Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)
1 ビュー
• 07/14/23
0
0
埋め込む
administrator
加入者
Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント